[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356832-105":59,"doc-detail-356832-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","five-year-outcomes-of-transoral-robotic-surgery-with-or-without-neoadjuvant-chemotherapy-in-laryngeal-squamous-cell-carcinoma-preliminary-experience","Five-year outcomes of transoral robotic surgery with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma - preliminary experience","","Organ preservation is a central objective in laryngeal cancer care, and transoral robotic surgery (TORS) combined with neoadjuvant chemotherapy (NACT) may broaden minimally invasive options, although long-term evidence is limited. This retrospective study assessed 5-year oncologic outcomes in 37 patients with laryngeal squamous cell carcinoma treated with TORS, with NACT given for advanced-stage disease, using Kaplan–Meier survival estimates and log-rank comparisons. Results report overall, disease-specific, and disease-free survival, plus laryngeal preservation rates over a mean 73-month follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/five-year-outcomes-of-transoral-robotic-surgery-with-or-without-neoadjuvant-chemotherapy-in-laryngeal-squamous-cell-carcinoma-preliminary-experience/356832/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/five-year-outcomes-of-transoral-robotic-surgery-with-or-without-neoadjuvant-chemotherapy-in-laryngeal-squamous-cell-carcinoma-preliminary-experience/356832.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study objective regarding TORS and NACT in laryngeal cancer?","Question",{"text":112,"@type":113},"To evaluate 5-year oncologic outcomes of TORS with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma, focusing on organ preservation and long-term control.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and what was the study design?",{"text":117,"@type":113},"Medical records of 37 LSCC patients treated with TORS between 2012 and 2017 were retrospectively collected, with NACT administered for advanced-stage disease according to the Park et al. protocol.",{"name":119,"@type":110,"acceptedAnswer":120},"What survival endpoints were analyzed?",{"text":121,"@type":113},"Overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were estimated using Kaplan–Meier methods, with differences tested by the log-rank test.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356832,1790182224,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","LaryngoLogy  \nACTA Otorhinolaryngologica Italica 2026;46(Suppl. 1):S82-S89; doi: 10. 14639/0392-100X-suppl.1- 46-2026-A2314  \nFive-year outcomes of transoral robotic surgery with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma: a preliminary experience  \nArmando De Virgilio1 , Piero Giuseppe Meliante2,3 , Luigi D’Avino3 , Se-Heon Kim4  \n1 Department of Sense Organs, “Sapienza” University of Rome, Rome, Italy; 2 Department of Neuroscience, Mental Health and Sense Organs (NESMOS), “Sapienza” University of Rome, Rome, Italy; 3 “V. Monaldi”Hospital, Azienda Ospedaliera Dei Colli, Naples, Italy;  \n4 Department of Otorhinolaryngology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea  \nReceived: March 22, 2026  \nAccepted: April 8, 2026  \nCorrespondence  \nArmando De Virgilio  \n[E-mail: armando.devirgilio@uniroma1.it](E-mail: armando.devirgilio@uniroma1.it)  \n[How to cite this article:](How to cite this article: De Virgilio A)[ De Virgilio A](How to cite this article: De Virgilio A), [Meliante GP](Meliante GP), D’Avino L, et al. Five-year outcomes of transoral robotic surgery with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma: a preliminary experience. Acta Otorhinolaryngol Ital 2026(Suppl. 1);46:S82-S89 . [https://](https://)[ ](https://)[doi.org/10.14639/0392-100X-suppl.1-46-2026-A2314](doi.org/10.14639/0392-100X-suppl.1-46-2026-A2314)  \n© Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale  \n OPEN ACCESS  \nThis is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: [https://creativecommons.org/licenses/by-nc](https://creativecommons.org/licenses/by-nc)nd/4.0/deed.en  \nCover figure. Intraoperative image of transoral robotic surgery supraglottic laryngectomy.  \nSummary  \nObjective. Organ preservation is a key goal in management of laryngeal cancer. The combination of neadjuvant chemotherapy (NACT) and transoral robotic surgery (TORS) may extend minimally invasive surgery indications, but long-term data remain limited. This study evaluated 5-year oncologic outcomes of TORS with or without NACT in laryngeal squamous cell carcinoma (LSCC) .  \nMethods. We retrospectively analysed 37 LSCC patients treated between 2012 and 2017 with TORS, with NACT administered in advanced-stage disease. Kaplan-Meier analysis was used to estimate overall (OS), disease-specific (DSS), and disease-free survival (DFS) . Survival differences were assessed using the log-rank test.  \nResults. Mean follow-up was 73 months. In patients treated by TORS alone, we observed one- , 3- , and 5-year OS and DSS of 100%, with one-year DFS of 88 .9% decreasing to 77.8% at 3-and  \nRole of neoadjuvant chemotherapy and TORS in laryngeal cancer  \n5-year, and 100% of laryngeal preservation rate. In patients with locally advanced cT3-4N+ cancer who underwent NACT followed by TORS, 5-year OS, DSS, and DFS were 82 .4%, 93 .3%, and 61 . 1%, respectively, with a 84 .4% 5-year laryngeal preservation rate.  \nConclusions. TORS provides excellent long-term oncologic control in early LSCC. The addition of NACT allows extension to advanced disease while maintaining high laryngeal preservation rates, supporting a multimodal organ-preserving strategy.  \nKeywords: laryngeal neoplasms, squamous cell carcinoma, robotic surgical procedures, neoadjuvant therapy, organ preservation  \nIntroduction  \nMore than 189,000 new cases of laryngeal cancer occur annually worldwide, corresponding to an age-standardised incidence rate of 3.5 per 100,000 1. Prior to the 1990s, the standard management for locally advanced laryngeal cancer consisted of total laryngectomy followed by postoperative radiotherapy 2. Nevertheless, the considerable quali","cbCaioGGjldLHPsS","https://ap.wps.com/l/cbCaioGGjldLHPsS","pdf",1371952,"English","# Summary\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and methods","[{\"question\":\"What is the study objective regarding TORS and NACT in laryngeal cancer?\",\"answer\":\"To evaluate 5-year oncologic outcomes of TORS with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma, focusing on organ preservation and long-term control.\"},{\"question\":\"How were patients selected and what was the study design?\",\"answer\":\"Medical records of 37 LSCC patients treated with TORS between 2012 and 2017 were retrospectively collected, with NACT administered for advanced-stage disease according to the Park et al. protocol.\"},{\"question\":\"What survival endpoints were analyzed?\",\"answer\":\"Overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were estimated using Kaplan–Meier methods, with differences tested by the log-rank test.\"}]","Five-year outcomes of transoral robotic surgery with or without neoadjuvant chemotherapy in laryngeal squamous cell carcinoma - preliminary experience | PDF",1790127549,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44ab59d52f5a4507a7ca095747471141.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfebc9ddba2bf5fcafeacee35feef1d4.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51dd7d1bfd4584575d010d4285db1db1.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5207e959241156778509e9f1b60febd2.webp",980,1306]